Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*
Structure of EBV LMP-2 426-434 (HLA-A*02:01)
Logo for Infectious disease
Infectious disease

EBV LMP-2 426-434 (HLA-A*02:01) CLGGLLTMV

Product number: EP08605_1

€105.00*

Prices excl. VAT plus shipping costs
Available, delivery time: 2-5 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Caution: For research use only. Not for use in humans.
Amount in mg
1
Add to Cart

Description

The EBV LMP-2 426–434 peptide (Sequence: CLGGLLTMV) is a highly characterized, immunodominant linear epitope derived from the Latent Membrane Protein 2 (LMP-2, UniProt ID: P13285) of Epstein-Barr Virus (EBV / Human Herpesvirus 4).

Restricted to HLA-A*02:01, this peptide serves as an essential tool for monitoring virus-specific T-cell immunity, evaluating memory CD8+ T-cell responses, and validating immunoncology or vaccine platforms targetting EBV-associated malignancies.

Key Features & Applications

Extensively Validated: Documented in over 115 scientific publications and evaluated across 240+ T-cell assays and 30+ MHC ligand assays (IEDB Epitope ID: 6568).

Structural Precision: Solved 3D crystal structure available (PDB ID: 3REW) for precise molecular modeling and binding affinity analysis.

Assay Compatibility: Ideal for use in ELISpot, ICS (Intracellular Cytokine Staining), tetramer staining, and functional T-cell activation assays.

Cross-Referenced Control Pools

This catalog peptide is also available as a core component in the following off-the-shelf peptides&elephants control pools:

TechData

Sequence: CLGGLLTMV
Gene: LMP2
Delivery: 2-5 days
C-Terminus: OH
N-Terminus: H
Amount: 1 mg
Counterion: TFA
Protein: Latent membrane protein
UniProt Id: P13285
IEDB Id: 6568
Species: Epstein-Barr virus (EBV; Human herpesvirus 4)
Allele: HLA-A*02:01
Application: T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication: Infectious disease, Cancer, Neuroscience
Purity: 95% HPLC-MS

Documents

Material data sheet Safety data sheet Storage and handling of peptides Probing of membranes with HRP

References

Bonifacius, Agnes, et al. "Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies." Molecular Therapy Oncology 34.3 (2026).

Ning, Jianfang et al. “Functional virus-specific memory T cells survey glioblastoma.” Cancer immunology, immunotherapy : CII vol. 71,8 (2022): 1863-1875. doi:10.1007/s00262-021-03125-w

Skip product gallery

More EBV LMP peptides

EBV (LMP2) Peptide Pool
EBV (LMP2) Peptide Pool
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285). LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts. Scientific Background LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen. This peptide pool is an ideal tool for: Characterizing patient-specific or vaccine-induced T cell responses Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies

€340.70*
EBV LMP-1 125-133 (HLA-A*02:01)
EBV LMP-1 125-133 (HLA-A*02:01)
Antigen Peptide EBV LMP-1 125-133 (HLA-A*02:01) YLLEMLWRL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP-2 340-349 (HLA-A*11:01)
EBV LMP-2 340-349 (HLA-A*11:01)
SSCSSCPLSK is a linear peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP-2 340-349 mutant (HLA-A*11:01) 348T
EBV LMP-2 340-349 mutant (HLA-A*11:01) 348T
SSCSSCPLTK is a linear mutated peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assay

From €105.00*
Details
EBV LMP-2 419-427 (HLA-A*24:02)
EBV LMP-2 419-427 (HLA-A*24:02)
Antigen Peptide EBV LMP-2 419-427 (HLA-A*24:02) TYGPVFMCL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP1 159-167 (HLA-A*02:01)
EBV LMP1 159-167 (HLA-A*02:01)
Antigen Peptide EBV LMP1 159-167 (HLA-A*02:01) YLQQNWWTL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP2 131-139 (HLA-A*24:02)
EBV LMP2 131-139 (HLA-A*24:02)
Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.

From €105.00*
Details
EBV LMP2 200-208 (HLA-B*40:01)
EBV LMP2 200-208 (HLA-B*40:01)
IEDPPFNSL is a linear peptidic epitope (epitope ID 25756) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP2 356-364 (HLA-A*02:01)
EBV LMP2 356-364 (HLA-A*02:01)
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus).

From €105.00*
Details
EBV LMP2 419-427 mutant 426S (HLA-A*24:02)
EBV LMP2 419-427 mutant 426S (HLA-A*24:02)
The peptide EBV LMP2 419-427 mutant 426S (HLA-A*24:02) with the amino acid sequence TYGPVFMSL is a linear peptidic epitope (epitope ID 67350) studied as part of Latent membrane protein 2 (UniProt:P13285) from Human herpesvirus 4 (Epstein Barr virus).EBV LMP2 419-427 mutant 426S (HLA-A*24:02) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

From €105.00*
Details
This website uses cookies to ensure the best experience possible. More information...